A Phase 1/2 interventional study of 64Cu-SAR-bisPSMA in Biochemical Recurrence of Malignant Neoplasm of Prostate, sponsored by Clarity Pharmaceuticals Ltd. Completed at 5 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-01.
Sponsored by Clarity Pharmaceuticals Ltd · Phase 1/2, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The aim of this study is to determine the safety and efficacy of 64Cu-SAR-bisPSMA and determine the ability of 64Cu-SAR-bisPSMA Positron emission tomography (PET)/computed tomography (CT) to correctly detect the recurrence of prostate cancer in participants with biochemical recurrence of prostate cancer following definitive therapy.
Participants with biochemical evidence of recurrence of PC were evaluated with 64CU-SAR-bisPSMA PET/CT (Day 0 and Day 1) and by conventional methodologies up to 180 days later, eg. Histopathology/biopsy, conventional imaging, PSA reduction post focal salvage therapy or radiotherapy with no concomitant androgen deprivation therapy. Three independent central readers blinded to the participant number, the time of the PET/CT scan and the results of the conventional methodologies assessed the 64Cu-SAR-bisPSMA PET/CT. Three separate independent readers assessed the results of the conventional methodologies.
Clarity Pharmaceuticals Ltd is the lead sponsor of 11 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Suspected recurrence of prostate cancer (PC) based on rising Prostate-specific antigen (PSA) after definitive therapy on the basis of:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will receive a single administration of 200 megabecquerels (MBq) of 64Cu-SAR-bisPSMA.
Drug: 64Cu-SAR-bisPSMA
64Cu-SAR-bisPSMA
Safety and Tolerability
Incidence and severity of Treatment-Emergent Adverse Events (TEAE) and Serious Adverse Events. Adverse Events were assessed by CTCAE version 5.0
Time frame: up to 7 days post injection
Participant-level Correct Detection Rate (CDR)- Day 0
The percentage of TP participants on the Day 0 scan out of all participants with a Day 0 scan.
Time frame: Day 0 (1- 4 hours) post injection
Participant-level CDR- Day 1
The percentage of TP participants on the Day 1 scan out of all participants with a Day 1 scan.
Time frame: Day 1 (24+/-6 Hours) post injection
Region-level Positive Predictive Value (PPV)- Day 0
The percentage of TP regions on the Day 0 scan out of all positive regions on the Day 0 scan.
Time frame: Day 0 (1- 4 hours)
Region-level PPV- Day 1
The percentage of TP regions on the Day 1 scan out of all positive regions on the Day 1 scan.
Time frame: Day 1 (24 +/- 6 hours)
Biodistribution of 64Cu-SAR-bisPSMA- SUVmean
The mean Standardized Uptake Value (SUVmean) in lesions, visceral soft tissue and bone.
Time frame: Day 0 (1 -4 hours) and Day 1 (24 +/- 6 hours) post injection
Biodistribution of 64Cu-SAR-bisPSMA- SUVmax
SUVmax in lesions, visceral soft tissue and bone
Time frame: Day 0 (1-4 hours) and Day 1 (24 +/- 6 hours)
Biodistribution of 64Cu-SAR-bisPSMA- SUVr
Lesion to Background ratio. SUVmax of the lesion divided by the SUVmean of gluteus background
Time frame: Day 0 (1-4 hours) and Day 1 (24 +/- 6 hours)
Participant-level PPV
Percentage of TP participants on the Day 0 or Day 1 scan out of all participants with a positive Day 0 or Day 1 scan.
Time frame: Day 0 (1-4 hours) and Day 1 (24 +/- 6 hours)
Participant-level Detection Rate (DR)
Percentage of participants with a positive Day 0 or Day 1 scan out of all participants with a Day 0 or Day 1 scan.
Time frame: Day 0 (1-4 hours) and Day 1 (24 +/- 6 hours)
Participant-level False Positive Rate (FPR)
Percentage of false positive (FP) participants on the Day 0 or Day 1 scan out of all participants with a positive Day 0 or Day 1 scan.
Time frame: Day 0 (1-4 hours) and Day 1 (24 +/- 6 hours)
Region-level FPR
Percentage of FP regions on the Day 0 or Day 1 scan out of all positive regions on the Day 0 or Day 1 scan.
Time frame: Day 0 (1-4 hours) and Day 1 (24 +/-6 hours)
Participant-level Discrepant PET Negativity Rate
Percentage of participants with contradicting Day 0 and Day 1 results for whom the Reference Standard was positive.
Time frame: Day 0 (1-4 hours) and Day 1 (24 +/-6 hours)
Participant-level True Negative Rate (TNR)
Percentage of TN participants on the Day 0 or Day 1 scan out of all participants with a negative Day 0 or Day 1 scan.
Time frame: Day 0 (1-4 hours) and Day 1 (24 +/-6 hours)
Region-level TNR
Percentage of TN regions on the Day 0 or Day 1 scan out of all negative regions on the Day 0 or Day 1 scan.
Time frame: Day 0 (1-4 hours) and Day 1 (24 +/- 6 hours)
Dates of recruitment period: 11 Apr 2022 to 23 Jan 2023
| Milestone | 64Cu-SAR-bisPSMA Injection |
|---|---|
| Started | 52 |
| Completed | 32 |
| Not completed | 20 |
| Withdrew: Protocol violation | 13 |
| Withdrew: Physician decision | 4 |
| Withdrew: Withdrawal by subject | 2 |
| Withdrew: Participant non-compliance | 1 |
Incidence and severity of Treatment-Emergent Adverse Events (TEAE) and Serious Adverse Events. Adverse Events were assessed by CTCAE version 5.0
| Participants | 64Cu-SAR-bisPSMA Injection |
|---|---|
| Any TEAE | 10 |
| TEAE Grade 1 to 2 | 8 |
| TEAE Grade 3 | 2 |
| TEAE Grade 4 to 5 | 0 |
| TEAE Related to 64Cu-SAR-bisPSMA | 1 |
| Serious TEAE | 1 |
| Serious TEAE related to Cu64-SAR-bisPSMA | 0 |
| TEAE leading to withdrawal from study | 0 |
| TEAE with fatal outcome | 0 |
The percentage of TP participants on the Day 0 scan out of all participants with a Day 0 scan.
| percentage of TP participants | 64Cu-SAR-bisPSMA |
|---|---|
| Reader 1 | 26.2 (13.9 to 42.0) |
| Reader 2 | 23.8 (12.1 to 39.5) |
| Reader 3 | 19.0 (8.6 to 34.1) |
The percentage of TP participants on the Day 1 scan out of all participants with a Day 1 scan.
| percentage of TP participants | 64Cu-SAR-bisPSMA PET Injection |
|---|---|
| Reader 1 | 33.3 (19.6 to 49.5) |
| Reader 2 | 33.3 (19.6 to 49.5) |
| Reader 3 | 26.2 (13.9 to 42.0) |
The percentage of TP regions on the Day 0 scan out of all positive regions on the Day 0 scan.
| percentage of TP regions | 64Cu-SAR-bisPSMA Injection |
|---|---|
| Reader 1 | 41.2 (24.6 to 59.3) |
| Reader 2 | 44.8 (26.4 to 64.3) |
| Reader 3 | 39.1 (19.7 to 61.5) |
The percentage of TP regions on the Day 1 scan out of all positive regions on the Day 1 scan.
| percentage of TP regions | 64Cu-SAR-bisPSMA Injection |
|---|---|
| Reader 1 | 41.5 (26.3 to 57.9) |
| Reader 2 | 32.7 (20.3 to 47.1) |
| Reader 3 | 43.3 (25.5 to 62.6) |
The mean Standardized Uptake Value (SUVmean) in lesions, visceral soft tissue and bone.
| g/mL | SUVmean- Day 0 | SUVmean - Day 1 |
|---|---|---|
| Reader 1 All Lesions | 9.898 ± 5.9588 | 15.818 ± 15.0800 |
| Reader 2 All Lesions | 8.990 ± 5.8339 | 14.678 ± 19.4486 |
| Reader 3 All Lesions | 6.635 ± 3.2447 | 14.729 ± 11.1719 |
| Reader 1 Bone Lesions | 9.188 ± 4.7099 | 17.699 ± 10.7888 |
| Reader 2 Bone Lesions | 8.611 ± 4.2796 | 10.503 ± 11.9074 |
| Reader 3 Bone Lesions | 7.283 ± 4.4456 | 19.408 ± 10.9045 |
| Reader 1 Soft Tissue Lesions | 9.706 ± 6.2907 | 15.56 ± 15.5137 |
| Reader 2 Soft Tissue Lesions | 9.018 ± 6.1432 | 15.402 ± 20.2457 |
| Reader 3 Soft Tissue Lesions | 6.386 ± 3.2565 | 14.093 ± 11.4177 |
SUVmax in lesions, visceral soft tissue and bone
| g/mL | SUVmax- Day 0 | SUVmax- Day 1 |
|---|---|---|
| Reader 1 All Lesions | 13.973 ± 8.9671 | 22.198 ± 18.6239 |
| Reader 2 All Lesions | 13.914 ± 10.3342 | 22.789 ± 32.3980 |
| Reader 3 All Lesions | 13.924 ± 7.6483 | 33.363 ± 37.7745 |
| Reader 1 Bone Lesions | 13.05 ± 6.4444 | 27.600 ± 17.7468 |
| Reader 2 Bone Lesions | 14.156 ± 6.0519 | 16.660 ± 17.9690 |
| Reader 3 Bone Lesions | 16.718 ± 5.0380 | 37.223 ± 19.9721 |
| Reader 1 Soft Tissue Lesions | 13.746 ± 9.5714 | 21.832 ± 19.2837 |
| Reader 2 Soft Tissue Lesions | 13.680 ± 11.1150 | 24.068 ± 33.7881 |
| Reader 3 Soft Tissue Lesions | 12.981 ± 8.1606 | 32.976 ± 39.5467 |
Lesion to Background ratio. SUVmax of the lesion divided by the SUVmean of gluteus background
| ratio | SUVr - Day 0 | SUVr - Day 1 |
|---|---|---|
| Reader 1 All Lesions | 23.233 ± 14.0537 | 118.051 ± 90.7403 |
| Reader 2 All Lesions | 23.476 ± 17.3919 | 121.306 ± 160.9991 |
| Reader 3 All Lesions | 25.448 ± 15.0785 | 181.673 ± 171.6481 |
Percentage of TP participants on the Day 0 or Day 1 scan out of all participants with a positive Day 0 or Day 1 scan.
| percentage of TP participants | Participant-level PPV- Day 0 | Participant-level PPV- Day 1 |
|---|---|---|
| Reader 1 | 44.0 (24.4 to 65.1) | 45.2 (27.3 to 64.0) |
| Rader 2 | 43.5 (23.2 to 65.5) | 40.0 (23.9 to 57.9) |
| Reader 3 | 42.1 (20.3 to 66.5) | 47.8 (26.8 to 69.4) |
Percentage of participants with a positive Day 0 or Day 1 scan out of all participants with a Day 0 or Day 1 scan.
| percentage of TP participants | Participant-level DR- Day 0 | Participant-level DR- Day 1 |
|---|---|---|
| Reader 1 | 58.0 (43.2 to 71.8) | 74.0 (59.7 to 85.4) |
| Reader 2 | 56.0 (41.3 to 70.0) | 80.0 (66.3 to 90.0) |
| Reader 3 | 44.0 (30.0 to 58.7) | 58.0 (43.2 to 71.8) |
Percentage of false positive (FP) participants on the Day 0 or Day 1 scan out of all participants with a positive Day 0 or Day 1 scan.
| percentage of FP participants | Participant-level FPR- Day 0 | Participant-level FPR- Day 1 |
|---|---|---|
| Reader 1 | 53.8 (33.4 to 73.4) | 54.8 (36.0 to 72.7) |
| Reader 2 | 54.2 (32.8 to 74.4) | 60.0 (42.1 to 76.1) |
| Reader 3 | 57.9 (33.5 to 79.7) | 50.0 (29.1 to 70.9) |
Percentage of FP regions on the Day 0 or Day 1 scan out of all positive regions on the Day 0 or Day 1 scan.
| percentage of FP regions | Region-level FPR-Day 0 | Region-level FPR-Day 1 |
|---|---|---|
| Reader 1 | 58.8 (40.7 to 75.4) | 57.1 (41.0 to 72.3) |
| Reader 2 | 55.2 (35.7 to 73.6) | 67.3 (52.9 to 79.7) |
| Reader 3 | 60.9 (38.5 to 80.3) | 56.7 (37.4 to 74.5) |
Percentage of participants with contradicting Day 0 and Day 1 results for whom the Reference Standard was positive.
| percentage of participants | 64Cu-SAR-bisPSMA Injection |
|---|---|
| Reader 1 | 14.3 (1.8 to 42.8) |
| Reader 2 | 21.4 (4.7 to 50.8) |
| Reader 3 | 42.9 (17.7 to 71.1) |
Percentage of TN participants on the Day 0 or Day 1 scan out of all participants with a negative Day 0 or Day 1 scan.
| percentage of TN participants | Participant-level TNR- Day 0 | Participant-level TNR- Day 1 |
|---|---|---|
| Reader 1 | 50.0 (30.6 to 69.4) | 39.3 (21.5 to 59.4) |
| Reader 2 | 53.6 (33.9 to 72.5) | 25.0 (10.7 to 44.9) |
| Reader 3 | 60.7 (40.6 to 78.5) | 57.1 (37.2 to 91.8) |
Percentage of TN regions on the Day 0 or Day 1 scan out of all negative regions on the Day 0 or Day 1 scan.
| percentage of TN regions | Region-level TNR-Day 0 | Region-level TNR- Day 1 |
|---|---|---|
| Reader 1 | 88.7 (83.1 to 93.0) | 86.4 (80.5 to 91.1) |
| Reader 2 | 91.0 (85.7 to 94.7) | 80.1 (73.4 to 85.7) |
| Reader 3 | 92.1 (87.2 to 95.6) | 90.4 (85.1 to 94.3) |
Collected over Up to 7 days post injection. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Safety Analysis Set | 0/52 (0%) | 1/52 (1.9%) | 0/52 (0%) |
| Event | Safety Analysis Set |
|---|---|
| urosepsisInfections and infestations | 1/52 |
All enrolled participants who received any amount of 64Cu-SAR-bisPSMA.
| Age, Categorical(Participants) | 64Cu-SAR-bisPSMA Injection |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 13 |
| >=65 years | 39 |
| Sex: Female, Male(Participants) | 64Cu-SAR-bisPSMA Injection |
|---|---|
| Female | 0 |
| Male | 52 |
| Ethnicity (NIH/OMB)(Participants) | 64Cu-SAR-bisPSMA Injection |
|---|---|
| Hispanic or Latino | 7 |
| Not Hispanic or Latino | 45 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | 64Cu-SAR-bisPSMA Injection |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 2 |
| White | 49 |
| More than one race | 0 |
| Unknown or Not Reported | 1 |
| Region of Enrollment(participants) | 64Cu-SAR-bisPSMA Injection |
|---|---|
| United States | 52 |
| Baseline PSA(ng/mL) | 64Cu-SAR-bisPSMA Injection |
|---|---|
| Mean | 2.973 ± 4.1722 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2022 to primary completion in Aug 2023, 15 months.
Results were first posted in Oct 2024, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Abefolastat tesaroxetan CU-64
Clarity Pharmaceuticals Ltd